Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer

PURPOSE: Etirinotecan pegol (NKTR-102) is a unique, long-acting topoisomerase-I inhibitor with prolonged systemic exposure to SN38 (7-ethyl-10-hydroxycamptothecin), the active metabolite of irinotecan. This randomized phase II trial investigated two dosing schedules of etirinotecan pegol in patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Vergote, Ignace B., Garcia, Agustin, Micha, John, Pippitt, Charles, Bendell, Johanna, Spitz, Daniel, Reed, Nicholas, Dark, Graham, Fracasso, Paula M., Ibrahim, Emad N., Armenio, Vincent A., Duska, Linda, Poole, Chris, Gennigens, Christine, Dirix, Luc Y., Leung, Abraham C.F., Zhao, Carol, Soufi-Mahjoubi, Raoudha, Rustin, Gordon
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2013
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878105/
https://ncbi.nlm.nih.gov/pubmed/24081946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.45.1278
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados